The full search strategy for Pubmed is as followings: We use the following search string: ("Ginkgo biloba"[Mesh] or "ginkgo"[tiab]) AND("Altitude Sickness"[Mesh] or "Altitude Sickness"[tiab] or "mountain"[tiab]) Supplementary Table 1. Secondary outcomes of included studies

		Incidence of severe AMS	Headache	Severe headache	Oxygen saturation	Pulmonary edema	Adverse events
Roncin, 1996	GBE	х	22/22 (100%)	0/22 (0%)	x	AMS-R >0.6 3/21 (13.6%)	GBE(18.2%) is less urine than Placebo(77.3%)
	Placebo	х	22/22 (100%)	0/22 (0%)	x	AMS-R >0.6 18/22 (81.8%)	
Gertsch, 2002	GBE	2/12 (16.7%)	х	1/12 (8%)	81%	х	No side effect in GBE
	Placebo	9/14 (64.3%)	х	1/14 (7%)	80%	x	
Gertsch, 2004	GBE	23/124 (18%)	72/124 (58%)	24/124 (19%)	79.5%	- Non occurred	No side effect in GBE
	Placebo	22/119 (18%)	63/119 (53%)	16/119 (13%)	82.1% P<0.01		
Chow, 2005	GBE	Х	GBE is 5% less than placebo		X	Non occurred	No side effect in GBE
	Placebo	х			х		
Moraga, 2007	GBE	х	LLS score, headache item 0.19±0.41		92±2%	x	x
	Placebo	Х	1.28±0.14 P<0.05		84±3% P<0.01	X	Х
Leadbetter, 2009(Study 1)	GBE	0/21 (0%)	х	Х	Х	X	Х
	Placebo	3/19 (16%)	х	х	Х	X	Х
Leadbetter, 2009(Study 2)	GBE	3/15 (20%)	х	х	X	X	Х
	Placebo	4/22 (18%)	Х	х	X	X	Х

AMS: Acute mountain sickness ; AMS-R: the Environmental Symptom Questionnaire III acute mountain sickness-Respiratory (AMS-R) score; GBE: ginkgo biloba extract; LLS: Lake Louise Score; X: not mentioned in the study.

Subgroup	Number of participants
Low risk of bias studies	357
Gertsch, 2004	
Chow, 2005	
Leadbetter, 2009	
Starting altitude below 2500m	208
Roncin, 1996	
Gertsch, 2002	
Chow, 2005	
Moraga, 2007	
Leadbetter, 2009	
3–5 days prior to ascent	114
Chow, 2005	
Leadbetter, 2009	
0–2 days prior to ascent	337
Roncin, 1996	
Gertsch, 2002	
Gertsch, 2004	
Moraga, 2007	
Dosage less than 200mg per day	94
Roncin, 1996	
Gertsch, 2002	
Moraga, 2007	
Dosage more than 200mg per day	357
Gertsch, 2004	
Chow, 2005	
Leadbetter, 2009	

Supplementary Table 2. Number of participants and enrolled studies in each subgroup